2022 Guide to Patient Support Services

Blueprint Medicines

Blueprint Medicines Support Services

888-258-7768

Blueprint Medicines offers the YourBlueprint patient support program to provide appropriate information and assistance to patients taking Ayvakit (Table).

YourBlueprint

YourBlueprint patient support program offers a QuickStart Program, Coverage Interruption Program, Ayvakit Dose Exchange Program, Co-pay Assistance Program, Patient Assistance Program, as well as a team of case managers, reimbursement specialists, and specialty pharmacy liaisons to assist your patients access treatment.

QuickStart Program

This program offers a temporary no-cost 15-day supply of medication in the event of a coverage-related delay. Patients may be eligible if they:

  • Are new to Ayvakit treatment
  • Have private/commercial or government insurance and are experiencing delays in coverage
  • Are enrolled in YourBlueprint.

Coverage Interruption Program

This program offers a no-cost 15-day supply of medication to patients already on therapy who face a temporary interruption in insurance coverage.

Ayvakit Dose Exchange Program

This program allows patients who have a change in their dose of Ayvakit to exchange remaining medication for the new dose.

Co-pay Assistance Program

Patients may be eligible for the Co-pay Assistance Program if they have commercial insurance with coverage for their prescription.

Patient Assistance Program

Patients may be eligible for the Patient Assistance Program if they:

  • Are uninsured or underinsured
  • Have a valid prescription for Ayvakit
  • Reside in the United States or a US territory
  • Meet certain financial and eligibility criteria.

Click here to learn more or to enroll your patient in YourBlueprint, or call 888-258-7768.

TABLE Blueprint Oncology Drug

Drug
Indications
Patient support programs

Drug
Ayvakit (avapritinib) tablets
Indications
Treatment of adults with unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations; treatment of adult patients with advanced systemic mastocytosis to include aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast-cell leukemia
Patient support programs

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"
Comments
(Optional)